As reported on Beckers Hospital Review, the U.S. Food and Drug Administration has authorized ensitrelvir (brand name Xocova) as the first oral antiviral indicated for post-exposure prophylaxis of COVID-19 in individuals aged 12 years and older. The decision marks a notable advancement in outpatient prevention options, offering an alternative to existing non-oral or pre-exposure strategies.
According to the agency’s announcement, Xocova is intended for use after close contact with someone infected with SARS-CoV-2. The regimen is administered over five days, beginning with a higher loading dose on the first day followed by once-daily dosing for the remainder of the course.
Clinical Evidence
Approval was supported by findings from the phase 3 SCORPIO-PEP trial, a randomized study evaluating the drug’s effectiveness in preventing symptomatic disease among individuals recently exposed to COVID-19. Results demonstrated a meaningful reduction in the likelihood of developing symptomatic infection. Participants who received ensitrelvir had approximately a two-thirds lower risk of developing symptoms within 10 days compared with those given placebo.
Investigators noted that this trial stands out as one of the first late-stage studies of an oral antiviral agent to successfully meet its primary endpoint for post-exposure prevention of COVID-19.
Safety Profile
The overall safety findings were comparable between treatment and placebo groups. Adverse events were reported at similar rates, with slightly more headaches, diarrhea, and cough observed in patients receiving Xocova. No major new safety concerns were identified.
Regulatory Timeline
The FDA completed its evaluation ahead of its target action date, issuing a decision roughly two weeks before the scheduled deadline. The clinical trial results underpinning the approval were published in mid-May in a peer-reviewed medical journal, adding further validation to the findings.
Implications for Practice
The availability of an oral post-exposure option may influence prevention strategies, particularly for high-risk populations or household contacts of infected individuals. Experts suggest that ease of administration and early intervention could improve adherence and reduce onward transmission, although real-world effectiveness will continue to be assessed.
As COVID-19 transitions toward endemic management, the introduction of a convenient antiviral prophylactic option highlights ongoing efforts to expand both treatment and prevention tools in outpatient care.
